Insights for COVID-19 in 2023.
Autor: Martín Sánchez, Francisco Javier; Martínez-Sellés, Manuel; Molero García, José María; Martín Delgado, María Cruz; Bouza, Emilio
Resumen: Predictions for a near end of the pandemic by the World
Health Organization should be interpreted with caution. Current evidence
indicates that the efficacy of a fourth dose of classical mRNA
vaccines (BT162b2 or mRNA-1273) is low and short-lived in preventing
SARS-CoV-2 infection in its predominant variant (Omicron).
However, its efficacy is high against severe symptomatic infection,
hospitalization and death. The new vaccines being introduced are
bivalent and active against the Omicron variants. Potential new
vaccines to be introduced in the coming year include a vaccine
based on a recombinant protein that emulates the receptor binding
domain of the Spike protein under development by the Spanish
company Hipra, as well as vaccines for nasal or oral administration.
Available information suggests that vaccines against COVID-19 can
be administered in association with influenza vaccination without
particular complications. New drugs against COVID-19, both antiviral
and anti-inflammatory, are under investigation, but this does
not seem to be the case with monoclonal antibodies. The indication
to use masks in some circumstances will be maintained next year in
view of the accumulation of scientific data on their efficacy. Finally,
the long COVID or Post-COVID syndrome may continue to affect a
very high proportion of patients who have had the disease, requiring
combined diagnostic and therapeutic resources.
Ficheros en el ítem
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
martin13dec2022.pdf | 183.7Kb | Ver/ |
Este ítem aparece en la(s) siguiente(s) colección(ones)
- MEDICINA [816]